New eczema drug ATTO-3712 enters early human safety trials
NCT ID NCT07205081
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new drug called ATTO-3712 in healthy adults and people with atopic dermatitis (eczema). The main goal is to check if the drug is safe and how the body processes it. Participants receive either the drug or a placebo and are monitored with clinic visits and symptom diaries.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS (AD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Altasciences
Montreal, Quebec, H3P 3P1, Canada
-
Attovia Clinical Site 102
Peterborough, Ontario, K9J 5K2, Canada
-
Attovia Clinical Site 202
Saint Joseph, Missouri, 64506, United States
-
Attovia Clinical Site 203
Encinitas, California, 92024, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can ozonated oil soothe eczema in kids?
- Can a Skin-Repairing cream soothe eczema?
- Can a new antibody calm severe eczema?
- Microscopic skin scans may reveal how a new eczema drug reshapes the skin
- Menthol gloves may offer quick itch relief for eczema sufferers
- One pill may tame both itchy skin and stubborn liver disease